........................................................................ 27
......................................................................... 30
.............................................................................. 31
NOODOPROEPEN .................................................................... 34
......................................................................... 35
........................................................................... 37
................................................................................. 38
-
(TOT) ............................................................... 39
........................................................................... 43
N-iv
) ................................................. 26
..................................................................... 29
..................................................................... 29
.................................................................. 30
..................................................................... 30
.......................................................... 31
.................................................................. 31
........................................................... 35
.............................................................. 36
.................................................................. 37
(BCL) ..................................................... 39
..................................................................... 39
.............................................................. 40
............................................................ 40
..................................................................... 41
............................................. 38
........................................... 40